Coronavirus Update: Alexion Tests Ultomiris in ARDS
Plus Novartis Begins Phase III Hydrochloroquine
More Phase III trials announced from Alexion and Novartis, while Karyopharm investigates potential of repurposed cancer therapy.
You may also be interested in...
FDA's Emergency Use Authorization for Malaria Drugs Could Hinder Trials of Other COVID-19 Treatments
Questions linger about the role the White House played in pushing the EUA, which comes with large product donations from Bayer and Sandoz that are expected to alleviate supply chain pressures for the drugs.
Efficacy trials are under way and one supplier already has said it would restart production to meet the anticipated demand.
Immediate interaction with US FDA after stressful advisory committee facilitated accelerated approval in fourth-line myeloma, company says. Four different dosing regimens will be priced at $22,000 for four weeks.